BofA raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Buy rating on the shares. The firm is positive on the company’s decision to remain disciplined on the external growth front, but acknowledges the markets concern that it may fall behind as others shift to an offensive strategy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue